{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=103",
    "query": {
      "condition": "Advanced Malignancy",
      "page": 103
    },
    "page_size": 10
  },
  "pagination": {
    "page": 103,
    "page_size": 10,
    "total_count": 9820,
    "total_pages": 982,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=104&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=102&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T22:24:22.263Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05329103",
      "title": "A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "PEEL-224",
          "type": "DRUG"
        },
        {
          "name": "FOLF+B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Peel Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2022-07-11",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-11-11T22:24:22.263Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Palo Alto, California • Huntersville, North Carolina + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05329103"
    },
    {
      "nct_id": "NCT00038103",
      "title": "Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Celecoxib + Exemestane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 111,
      "start_date": "2002-01",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2010-02-25",
      "last_synced_at": "2026-11-11T22:24:22.263Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00038103"
    },
    {
      "nct_id": "NCT01204203",
      "title": "Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma"
      ],
      "interventions": [
        {
          "name": "Zometa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2009-06",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-05-24",
      "last_synced_at": "2026-11-11T22:24:22.263Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01204203"
    },
    {
      "nct_id": "NCT03907527",
      "title": "Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Ovarian Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Refractory Fallopian Tube Carcinoma",
        "Refractory Ovarian Carcinoma",
        "Refractory Primary Peritoneal Carcinoma",
        "Stage III Fallopian Tube Cancer AJCC V8",
        "Stage III Ovarian Cancer AJCC V8",
        "Stage III Primary Peritoneal Cancer AJCC V8",
        "Stage IIIA Fallopian Tube Cancer AJCC V8",
        "Stage IIIA Ovarian Cancer AJCC V8",
        "Stage IIIA Primary Peritoneal Cancer AJCC V8",
        "Stage IIIA1 Fallopian Tube Cancer AJCC V8",
        "Stage IIIA1 Ovarian Cancer AJCC V8",
        "Stage IIIA2 Fallopian Tube Cancer AJCC V8",
        "Stage IIIA2 Ovarian Cancer AJCC V8",
        "Stage IIIB Fallopian Tube Cancer AJCC V8",
        "Stage IIIB Ovarian Cancer AJCC V8",
        "Stage IIIB Primary Peritoneal Cancer AJCC V8",
        "Stage IIIC Fallopian Tube Cancer AJCC V8",
        "Stage IIIC Ovarian Cancer AJCC V8",
        "Stage IIIC Primary Peritoneal Cancer AJCC V8",
        "Stage IV Fallopian Tube Cancer AJCC V8",
        "Stage IV Ovarian Cancer AJCC V8",
        "Stage IV Primary Peritoneal Cancer AJCC V8",
        "Stage IVA Fallopian Tube Cancer AJCC V8",
        "Stage IVA Ovarian Cancer AJCC V8",
        "Stage IVA Primary Peritoneal Cancer AJCC V8",
        "Stage IVB Fallopian Tube Cancer AJCC V8",
        "Stage IVB Ovarian Cancer AJCC V8",
        "Stage IVB Primary Peritoneal Cancer AJCC V8"
      ],
      "interventions": [
        {
          "name": "PRGN-3005 UltraCAR-T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Precigen, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 71,
      "start_date": "2019-04-30",
      "completion_date": "2028-11-15",
      "has_results": false,
      "last_update_posted_date": "2024-11-08",
      "last_synced_at": "2026-11-11T22:24:22.263Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Seattle, Washington",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03907527"
    },
    {
      "nct_id": "NCT06546969",
      "title": "Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Biliary Tract Cancer",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Spatially Fractionated RT",
          "type": "RADIATION"
        },
        {
          "name": "Deep Hyperthermia",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "DEVICE"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2024-10-29",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-11-11T22:24:22.263Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06546969"
    },
    {
      "nct_id": "NCT00003254",
      "title": "SWOG-S9635 Fluorouracil Plus Ethynyluracil in Advanced Colorectal Cancer Not Responded to Fluorouracil",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "ethynyluracil",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "1998-04",
      "completion_date": "2003-10",
      "has_results": false,
      "last_update_posted_date": "2012-03-08",
      "last_synced_at": "2026-11-11T22:24:22.263Z",
      "location_count": 86,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003254"
    },
    {
      "nct_id": "NCT00622505",
      "title": "Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "zoledronic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2007-11-07",
      "completion_date": "2012-04-03",
      "has_results": true,
      "last_update_posted_date": "2021-05-26",
      "last_synced_at": "2026-11-11T22:24:22.263Z",
      "location_count": 42,
      "location_summary": "Casa Grande, Arizona • La Verne, California • Los Angeles, California + 36 more",
      "locations": [
        {
          "city": "Casa Grande",
          "state": "Arizona"
        },
        {
          "city": "La Verne",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "San Gabriel",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00622505"
    },
    {
      "nct_id": "NCT07472322",
      "title": "ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Merkel Cell Carcinoma",
        "Merkel Cell Carcinoma, Stage III",
        "Merkel Cell Carcinoma, Stage IV"
      ],
      "interventions": [
        {
          "name": "ASTX727 + retifanlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2026-11",
      "completion_date": "2031-05",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-11T22:24:22.263Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07472322"
    },
    {
      "nct_id": "NCT05200572",
      "title": "Study of a Behavioral Intervention for Older Advanced Cancer Patients and Their Caregivers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer, Advanced",
        "Cognitive Impairment, Mild"
      ],
      "interventions": [
        {
          "name": "Dyadic Life Review (DLR)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2022-03-28",
      "completion_date": "2024-05-24",
      "has_results": true,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-11-11T22:24:22.263Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05200572"
    },
    {
      "nct_id": "NCT03699319",
      "title": "CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "CPI 613",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "5-flurouracil",
          "type": "DRUG"
        },
        {
          "name": "Folinic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David Bajor, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 49,
      "start_date": "2018-12-07",
      "completion_date": "2024-09-23",
      "has_results": false,
      "last_update_posted_date": "2025-01-23",
      "last_synced_at": "2026-11-11T22:24:22.263Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03699319"
    }
  ]
}